Beta-Blockers in Hypertension: Should We Discard Them? CME

Author Information and Disclosures

Release Date: April 17, 2008; Valid for credit through April 17, 2009

Credits Available
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Beta-Blockers in Hypertension: Should We Discard Them?John S. Schroeder, MD, FACCPeter C. Block, MD, FACC

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

The American College of Cardiology Foundation is not responsible for statements made by any contributor. Statements or opinions expressed in this program reflect the views of the contributors and do not reflect the official policy of the American College of Cardiology Foundation.

The questions and answers in Cardiosource were designed to stimulate thinking and motivate readers to further research. Answers and commentaries are based on the best judgment of the author at the time the question was written. New knowledge, insights and perspectives may cause the reader to disagree with an author's answer. The American College of Cardiology Foundation encourages thoughtful discussion and consideration of each question's answer and commentary.

Copyright © 2008 American College of Cardiology.
American College of Cardiology Foundation
Learning Objectives

Upon completion of this activity, the reader should be able to discuss the use of beta-blockers in treating hypertension including appropriate use and situations where the data suggest this class of drugs may be inappropriate.


Authors and Disclosures

John S. Schroeder, MD, FACC
Disclosure: John S. Schroeder, MD, FACC, Speaker Panel: Pfizer, Boehringer Ingelheim, Monarch, Glaxo; Consulting Fees: Aventis; Research Grants: Medtronic.


Peter C. Block, MD, FACC
Disclosure: Peter C. Block, MD, FACC has nothing to disclose.
 
ACC
The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Cardiology Foundation takes responsibility for the content, quality and scientific integrity of this CME activity. This CME activity was planned and produced in accordance with the ACCME Essential Areas and Elements.

The American College of Cardiology Foundation designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.